Shandong Chengchuang Blue Ocean Pharmaceutical Technology Co., Ltd.

Primary Objective: To conduct a bioequivalence study comparing a single oral dose of dapagliflozin tablets (test formulation T, owned by Shandong Chengchuang Blue Ocean Pharmaceutical Technology Co., Ltd. and manufactured by Yuanda Life Sciences (Shandong) Co., Ltd., strength: 10 mg/tablet) with dapagliflozin tablets (reference formulation R, owned by AstraZeneca AB and manufactured by AstraZeneca Pharmaceuticals LP, trade name: Andatang®/FORXIGA®, strength: 10 mg/tablet) in healthy study participants after a meal. The study aimed to investigate the rate and extent of absorption of the test formulation and the reference formulation in humans and to evaluate their bioequivalence. Secondary Objective: To observe the safety of the test formulation and the reference formulation (dapagliflozin tablets) in healthy study participants.

Primary objective: To evaluate the effectiveness of the test preparation on adult male primary premature ejaculation patients using lidocaine prilocaine aerosol developed by Anhui Jiexi Pharmaceutical Co., Ltd. as the test preparation, and lidocaine prilocaine aerosol (trade name: Fortacin®) licensed by Recordati Ireland Ltd. as the reference preparation, and placebo as the control. Secondary objective: To evaluate the effectiveness and safety of lidocaine prilocaine aerosol test preparation and reference preparation (trade name: Fortacin®) in adult male primary premature ejaculation subjects.

Primary objective Using the lidocaine prilocaine aerosol (trade name: Fortacin®) licensed by Recordati Ireland Ltd. as the reference preparation and the lidocaine prilocaine aerosol provided by Anhui Jiexi Pharmaceutical Co., Ltd. as the test preparation, a comparative study of the pharmacokinetic (PK) characteristics of a single dose in healthy Chinese male subjects was conducted. Secondary objective To evaluate the safety of the reference preparation and the test preparation in a single dose in healthy Chinese male subjects.